Evidence
Am J Nucl Med Mol Imaging. 2024 Feb 20;14(1):41-47. eCollection 2024.
ABSTRACT
Poly(ADP-ribose) polymerase (PARP) activation often indicates a disruptive signal to lipid metabolism, the physiological alteration of which may be implicated in the development of non-alcoholic fatty liver disease. The objective of this study was to evaluate the capability of [68Ga]DOTA-PARPi PET to detect hepatic PARP expression in a non-alcoholic steatohepatitis (NASH) mouse model. In this study, male C57BL/6 mice were subjected to a choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD) for a 12-week period to establish preclinical NASH models. [68Ga]DOTA-PARPi PET imaging of the liver was conducted at the 12-week mark after CDAHFD feeding. Comprehensive histopathological analysis, covering hepatic steatosis, inflammation, fibrosis, along with blood biochemistry, was performed in both NASH models and control groups. Despite the induction of severe inflammation, steatosis and fibrosis in the liver of mice with the CDAHFD-NASH model, PET imaging of NASH with [68Ga]-DOTA-PARPi did not reveal a significantly higher uptake in NASH models compared to the control. This underscores the necessity for further development of new chelator-based PARP1 tracers with high binding affinity to enable the visualization of PARP1 changes in NASH pathology.
PMID:38500745 | PMC:PMC10944370
Add to Google Keep
Estimated reading time: 4 minute(s)
Latest: Psychiatryai.com #RAISR4D
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
Poly(ADP-ribose) polymerase (PARP)-targeted PET imaging in non-oncology application: a pilot study in preclinical models of nonalcoholic steatohepatitis
🌐 90 Days
VR Related Evidence Matrix
- A CDAHFD-induced mouse model mimicking human NASH in the metabolism of hepatic phosphatidylcholines and acyl carnitines
- The protective effects of Ninjin'yoeito against liver steatosis/fibrosis in a non-alcoholic steatohepatitis model mouse
- Gypenoside XIII regulates lipid metabolism in HepG2 hepatocytes and ameliorates nonalcoholic steatohepatitis in mice
- Evaluation of Antisense Oligonucleotides Therapy Targeting Hsd17b13 in a Fibrosis Mice Model
- Role of autophagy in betaine-promoted hepatoprotection against non-alcoholic fatty liver disease in mice
- Hedan tablet ameliorated non-alcoholic steatohepatitis by moderating NF-kappaB and lipid metabolism-related pathways via regulating hepatic metabolites
- 6-Shogaol Ameliorates Liver Inflammation and Fibrosis in Mice on a Methionine- and Choline-Deficient Diet by Inhibiting Oxidative Stress, Cell Death, and Endoplasmic Reticulum Stress
- Time-Restricted Feeding Ameliorates Methionine-Choline Deficient Diet-Induced Steatohepatitis in Mice
- Yanggan Jiangmei Formula alleviates hepatic inflammation and lipid accumulation in non-alcoholic steatohepatitis by inhibiting the NF-kappaB/NLRP3 signaling pathway
- Lipidomic signatures discriminate subtle hepatic changes in the progression of porcine non-alcoholic steatohepatitis
- Potent Efficacy of 3-Amino-4-hydroxy Benzoic Acid, a Small Molecule Having Anti-fibrotic Activity, in a Mouse Model of Non-alcoholic Steatohepatitis
- Ablation of histone methyltransferase Suv39h2 in hepatocytes attenuates NASH in mice
- Targeted platelet with hydrogen peroxide responsive behavior for non-alcoholic steatohepatitis detection
- Indoleamine 2,3-dioxygenase 1-mediated iron metabolism in macrophages contributes to lipid deposition in nonalcoholic steatohepatitis
- Human umbilical cord mesenchymal stem cells attenuate diet-induced obesity and NASH-related fibrosis in mice
- A study of the anti-fibrotic effect of ghrelin on mice with nonalcoholic steatohepatitis
- DEAD-Box Helicase 17 exacerbates non-alcoholic steatohepatitis via transcriptional repression of cyp2c29, inducing hepatic lipid metabolism disorder and eliciting the activation of M1 macrophages
- Vitamin K2 protects mice against non-alcoholic fatty liver disease induced by high-fat diet
- Gentiopicroside improves non-alcoholic steatohepatitis by activating PPARalpha and suppressing HIF1
- Albumin-fused thioredoxin ameliorates high-fat diet-induced non-alcoholic steatohepatitis
- Dynamics of cellular plasticity in non-alcoholic steatohepatitis (NASH)
- Lipidomic Analysis of Liver and Adipose Tissue in a High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease Mice Model Reveals Alterations in Lipid Metabolism by Weight Loss and Aerobic Exercise
- SHMT2 reduces fatty liver but is necessary for liver inflammation and fibrosis in mice
- SHMT2 reduces fatty liver but is necessary for liver inflammation and fibrosis in mice
- Identification of pyroptosis-related gene signature in nonalcoholic steatohepatitis
- Development of non-alcoholic steatohepatitis is associated with gut microbiota but not with oxysterol enzymes CH25H, EBI2, or CYP7B1 in mice
- Cyclophilin D knockout significantly prevents HCC development in a streptozotocin-induced mouse model of diabetes-linked NASH
- Oral supplementation of gut microbial metabolite indole-3-acetate alleviates diet-induced steatosis and inflammation in mice
- An herbal formulation "Shugan Xiaozhi decoction" ameliorates methionine/choline deficiency-induced nonalcoholic steatohepatitis through regulating inflammation and apoptosis-related pathways
- Dietary intervention reverses molecular markers of hepatocellular senescence in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH
- Amphiregulin from regulatory T cells promotes liver fibrosis and insulin resistance in non-alcoholic steatohepatitis
- Semaglutide alters gut microbiota and improves NAFLD in db/db mice
- Sesamin ameliorates nonalcoholic steatohepatitis through inhibiting hepatocyte pyroptosis in vivo and in vitro
- Changes in Macronutrients during Dieting Lead to Weight Cycling and Metabolic Complications in Mouse Model
- Trim21 deficiency in mice increases HCC carcinogenesis in a NASH context and is associated with immune checkpoint upregulation
- Exercise ameliorates lipid droplet metabolism disorder by the PLIN2-LIPA axis-mediated lipophagy in mouse model of non-alcoholic fatty liver disease
- Extract of Silphium perfoliatum L. improve lipid accumulation in NAFLD mice by regulating AMPK/FXR signaling pathway
- Iron metabolism and ferroptosis in Non-alcoholic fatty liver disease: what is our next step?
- Anthocyanin: A Potential Phytochemical Candidate for the Amelioration of Non-Alcoholic Fatty Liver Disease
- Non-contrast T1ρ dispersion versus Gd-EOB-DTPA-enhanced T1mapping for the risk stratification of non-alcoholic fatty liver disease in rabbit models
- The role of extracellular vesicles in non-alcoholic steatohepatitis: Emerging mechanisms, potential therapeutics and biomarkers
- Antifibrotic activity of carbon quantum dots in a human in vitro model of non-alcoholic steatohepatitis using hepatic stellate cells
- Impact of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) on the expression and function of hepatobiliary transporters: A comprehensive mechanistic review
- Therapeutic effect of long-acting FGF21 with controlled site-specific modification on nonalcoholic steatohepatitis
- A Composite Blood Biomarker Including AKR1B10 and Cytokeratin 18 for Progressive Types of Nonalcoholic Fatty Liver Disease
- Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis
- Autophagy and the unfolded protein response shape the non-alcoholic fatty liver landscape: decoding the labyrinth
- Beneficial Effects of Dietary Flaxseed on Non-Alcoholic Fatty Liver Disease
- Paeonol attenuates nonalcoholic steatohepatitis by regulating intestinal flora and AhR/NLRP3/Caspase-1 metabolic pathway
- NAFLD and NASH: etiology, targets and emerging therapies
- Quantitative Brain Amyloid PET
- Lactobacillus Casei-fermented Amomum Xanthioides Mitigates non-alcoholic fatty liver disease in a high-fat diet mice model
- THE GLOBAL EPIDEMIOLOGY OF NON-ALCOHOLIC FATTY LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS AMONG PATIENTS WITH TYPE 2 DIABETES
- Hepatic Zbtb18 (Zinc Finger and BTB Domain Containing 18) alleviates hepatic steatohepatitis via FXR (Farnesoid X Receptor)
- Inhibition of ACOX1 enhances the therapeutic efficacy of obeticholic acid in treating non-alcoholic fatty liver disease and mitigates its lipotoxicity
- Xiaozhi Formula Attenuates Non-Alcoholic Fatty Liver Disease by Regulating Lipid Metabolism via Activation of AMPK and PPAR pathways
- Xiaozhi Formula Attenuates Non-Alcoholic Fatty Liver Disease by Regulating Lipid Metabolism via Activation of AMPK and PPAR pathways
- Lactiplantibacillus plantarum ZDY2013 Inhibits the Development of Non-Alcoholic Fatty Liver Disease by Regulating the Intestinal Microbiota and Modulating the PI3K/Akt Pathway
- Research progress, challenges and perspectives of phospholipids metabolism in the LXR‑LPCAT3 signaling pathway and its relation to NAFLD (Review)
- Long-term intermittent hypoxia in mice induces inflammatory pathways implicated in sleep apnea and steatohepatitis in humans
- The Protease Activated Receptor 2 - CCAAT/Enhancer-Binding Protein beta - SerpinB3 axis inhibition as a novel strategy for the treatment of Non-Alcoholic Steatohepatitis
- Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disease in mice
- Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disease in mice
- Mechanisms of 5-HT receptor antagonists in the regulation of fibrosis in a 3D human liver spheroid model
Evidence Blueprint
Poly(ADP-ribose) polymerase (PARP)-targeted PET imaging in non-oncology application: a pilot study in preclinical models of nonalcoholic steatohepatitis
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Poly(ADP-ribose) polymerase (PARP)-targeted PET imaging in non-oncology application: a pilot study in preclinical models of nonalcoholic steatohepatitis
🌐 365 Days
VR Related Evidence Matrix
- A CDAHFD-induced mouse model mimicking human NASH in the metabolism of hepatic phosphatidylcholines and acyl carnitines
- The protective effects of Ninjin'yoeito against liver steatosis/fibrosis in a non-alcoholic steatohepatitis model mouse
- Gypenoside XIII regulates lipid metabolism in HepG2 hepatocytes and ameliorates nonalcoholic steatohepatitis in mice
- Therapeutic effect of fenofibrate for non-alcoholic steatohepatitis in mouse models is dependent on regime design
- Evaluation of Antisense Oligonucleotides Therapy Targeting Hsd17b13 in a Fibrosis Mice Model
- Role of autophagy in betaine-promoted hepatoprotection against non-alcoholic fatty liver disease in mice
- Hedan tablet ameliorated non-alcoholic steatohepatitis by moderating NF-kappaB and lipid metabolism-related pathways via regulating hepatic metabolites
- Perilipin5 protects against non-alcoholic steatohepatitis by increasing 11-Dodecenoic acid and inhibiting the occurrence of ferroptosis
- A small animal model of NASH with progressive steatohepatitis -induced by fast food diet and alcohol in C57BL/6J mouse with high human pathophysiological proximity
- 6-Shogaol Ameliorates Liver Inflammation and Fibrosis in Mice on a Methionine- and Choline-Deficient Diet by Inhibiting Oxidative Stress, Cell Death, and Endoplasmic Reticulum Stress
- Time-Restricted Feeding Ameliorates Methionine-Choline Deficient Diet-Induced Steatohepatitis in Mice
- PARPs and ADP-Ribosylation in Chronic Inflammation: A Focus on Macrophages
- Targeting hepatic ceruloplasmin mitigates nonalcoholic steatohepatitis by modulating bile acid metabolism
- Yanggan Jiangmei Formula alleviates hepatic inflammation and lipid accumulation in non-alcoholic steatohepatitis by inhibiting the NF-kappaB/NLRP3 signaling pathway
- Longitudinal analysis of a dietary mouse model of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)
- Lipidomic signatures discriminate subtle hepatic changes in the progression of porcine non-alcoholic steatohepatitis
- Novel oral SPT inhibitor CH5169356 inhibits hepatic stellate cell activation and ameliorates hepatic fibrosis in mouse models of non-alcoholic steatohepatitis (NASH)
- A high-trans fat, high-carbohydrate, high-cholesterol, high-cholate diet-induced nonalcoholic steatohepatitis mouse model and its hepatic immune response
- Pilot randomized trial of an acceptance-based telehealth intervention for women with ovarian cancer and PARP inhibitor-related fatigue
- Potent Efficacy of 3-Amino-4-hydroxy Benzoic Acid, a Small Molecule Having Anti-fibrotic Activity, in a Mouse Model of Non-alcoholic Steatohepatitis
- Endoglin and soluble endoglin in liver sinusoidal endothelial dysfunction in vivo
- Ablation of histone methyltransferase Suv39h2 in hepatocytes attenuates NASH in mice
- Targeted platelet with hydrogen peroxide responsive behavior for non-alcoholic steatohepatitis detection
- Beneficial Effects of a Curcumin Derivative and Transforming Growth Factor-β Receptor I Inhibitor Combination on Nonalcoholic Steatohepatitis
- Utility of ultrasonography in a mouse model of non-alcoholic steatohepatitis induced by a choline-deficient, high-fat diet and dextran sulfate sodium
- Dietary Long-Chain Fatty Acids Accelerate Metabolic Dysfunction in Guinea Pigs with Non-Alcoholic Steatohepatitis
- Indoleamine 2,3-dioxygenase 1-mediated iron metabolism in macrophages contributes to lipid deposition in nonalcoholic steatohepatitis
- Endothelial autophagy is not required for liver regeneration after partial hepatectomy in mice with fatty liver
- Human umbilical cord mesenchymal stem cells attenuate diet-induced obesity and NASH-related fibrosis in mice
- A study of the anti-fibrotic effect of ghrelin on mice with nonalcoholic steatohepatitis
- DEAD-Box Helicase 17 exacerbates non-alcoholic steatohepatitis via transcriptional repression of cyp2c29, inducing hepatic lipid metabolism disorder and eliciting the activation of M1 macrophages
- Isoquercitrin attenuates the progression of non-alcoholic steatohepatitis in mice by modulating galectin-3-mediated insulin resistance and lipid metabolism
- Overexpression of Interleukin-8 Promotes the Progression of Fatty Liver to Nonalcoholic Steatohepatitis in Mice
- Alternative pathway of bile acid biosynthesis contributes to ameliorate NASH after induction of NAMPT/NAD+/SIRT1 axis
- Gluten worsens non-alcoholic fatty liver disease by affecting lipogenesis and fatty acid oxidation in diet-induced obese apolipoprotein E-deficient mice
- Visco-Elastic Parameters at Three-Dimensional MR Elastography for Diagnosing Non-Alcoholic Steatohepatitis and Substantial Fibrosis in Mice
- Resmetirom: An Orally Administered, Smallmolecule, Liver-directed, β-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis
- Itaconic acid underpins hepatocyte lipid metabolism in non-alcoholic fatty liver disease in male mice
- Herpetrione, a New Type of PPARα Ligand as a Therapeutic Strategy Against Nonalcoholic Steatohepatitis
- Alterations of hepatic energy metabolism in murine models of obesity, diabetes and fatty liver diseases
- Protectin D1 inhibits TLR4 signaling pathway to alleviate non-alcoholic steatohepatitis via upregulating IRAK-M
- Ginsenoside Rk3 Regulates Nonalcoholic Steatohepatitis by Modulation of Intestinal Flora and the PI3K/AKT Signaling Pathway in C57BL/6 Mice
- Whole-genome DNA methylation and gene expression profiling in the livers of mice with nonalcoholic steatohepatitis
- FMO2 ameliorates nonalcoholic fatty liver disease by suppressing ER-to-Golgi transport of SREBP1
- Liraglutide With Metformin Therapy Ameliorates Hepatic Steatosis and Liver Injury in a Mouse Model of Non-alcoholic Steatohepatitis
- Host ALDH2 deficiency aggravates nonalcoholic steatohepatitis through gut-liver axis
- Formononetin promotes fatty acid β-oxidation to treat non-alcoholic steatohepatitis through SIRT1/PGC-1α/PPARα pathway
- Pharmacological and genetic increases in liver NADPH levels ameliorate NASH progression in female mice
- Circulatory bone morphogenetic protein (BMP) 8B is a non-invasive predictive biomarker for the diagnosis of non-alcoholic steatohepatitis (NASH)
- High-fat diet promotes liver tumorigenesis via palmitoylation and activation of AKT
- AN1284 attenuates steatosis, lipogenesis, and fibrosis in mice with pre-existing non-alcoholic steatohepatitis and directly affects aryl hydrocarbon receptor in a hepatic cell line
- Vitamin K2 protects mice against non-alcoholic fatty liver disease induced by high-fat diet
- Protective effects of the succinate/SUCNR1 axis on damaged hepatocytes in NAFLD
- Time-restricted feeding ameliorates MCDD-induced steatohepatitis in mice
- Lipidomics in pathogenesis, progression and treatment of nonalcoholic steatohepatitis (NASH): Recent advances
- Gentiopicroside improves non-alcoholic steatohepatitis by activating PPARalpha and suppressing HIF1
- Albumin-fused thioredoxin ameliorates high-fat diet-induced non-alcoholic steatohepatitis
- Semaglutide reduces tumor burden in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH-HCC with advanced fibrosis
- MiR-182-5p Is Upregulated in Hepatic Tissues from a Diet-Induced NAFLD/NASH/HCC C57BL/6J Mouse Model and Modulates Cyld and Foxo1 Expression
- Overexpression of ORMDL3 confers sexual dimorphism in diet-induced non-alcoholic steatohepatitis
- Increased expression of sodium-glucose cotransporter 2 and O-GlcNAcylation in hepatocytes drives non-alcoholic steatohepatitis
- Dynamics of cellular plasticity in non-alcoholic steatohepatitis (NASH)
- Mitigation of non-alcoholic steatohepatitis via recombinant Orosomucoid 2, an acute phase protein modulating the Erk1/2-PPARγ-Cd36 pathway
- Lipidomic Analysis of Liver and Adipose Tissue in a High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease Mice Model Reveals Alterations in Lipid Metabolism by Weight Loss and Aerobic Exercise